Pathophysiology and diagnostic value of urinary trypsin inhibitors

References

1 Hochstrasser K, Wachter E, Bretzel G. Liberation of Kunitz-type inhibitors from the inter-alpha-trypsin-inhibitor by limited proteolysis. Proc FEBS 1977; 47: 225–34. Search in Google Scholar

2 Bost F, Diarra-Mehrpour M, Martin JP. Inter-alpha-trypsin inhibitor proteoglycan family-A group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem 1998; 252: 339–46. 10.1046/j.1432-1327.1998.2520339.xSearch in Google Scholar

3 Fries E, Kaczmarczyk A. Inter-alpha-inhibitor, hyaluronan and inflammation. Acta Biochim Pol 2003; 50: 735–42. 10.18388/abp.2003_3664Search in Google Scholar

4 Salier JP, Rouet P, Raguenez G, Daveau M. The inter-alpha-inhibitor family: from structure to regulation. Biochem J 1996; 315: 1–9. 10.1042/bj3150001Search in Google Scholar

5 Bauer J, Reich Z III. Antitryptic action of urine. Med Klin 1909; 5: 1744–7. Search in Google Scholar

6 Fries E, Blom AM. Bikunin – not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 2000; 32: 125–37. 10.1016/S1357-2725(99)00125-9Search in Google Scholar

7 Faarvang HJ. Urinary trypsin inhibitor in man. Scand J Clin Lab Invest 1965; 120: 1–83. Search in Google Scholar

8 Endo Y. Antishock action of ulinastatin. Surg Trauma Immunol Response 2003; 12: 29–38. Search in Google Scholar

9 Kato K. Human urinary trypsin inhibitor: its structure, biochemical properties and biosynthesis. Igaku Yakugaku 1995; 33: 1089–97. Search in Google Scholar

10 Ishizaki T, Ameshima S. Protease inhibitors. Kokyu 1993; 12: 686–97. Search in Google Scholar

11 Sakagami Y, Hoshi H. Biological function of protease inhibitors. Koso Kogaku 1993; 1: 187–201. Search in Google Scholar

12 Szczeklik A, Szewczuk A. Proteolytic enzyme inhibitors from human plasma and serum. Postepy Hig Med Dosw 1972; 26: 731–49. Search in Google Scholar

13 Vetr H, Gebhard W. Structure of the human alpha-1-microglobulin-bikunin gene. Hoppe-Seyler Biol Chem 1990; 371: 1185–96. 10.1515/bchm3.1990.371.2.1185Search in Google Scholar

14 Kuwajima S, Matsui T, Kitahashi S, Kishida T, Noda T, Izumi Y, et al. Urinary trypsin inhibitor and its clinical usefulness for diagnosis of acute phase reactant and renal disease. Ensho 1989; 9: 175–82. 10.2492/jsir1981.9.175Search in Google Scholar

15 Kuwajima S, Noda T, Izumi Y, Kitao H, Naka K, Okuda K. Urinary trypsin inhibitor as an acute phase reactant. Rinsho Byori 1992; 40: 751–5. Search in Google Scholar

16 Merle M, Jeandel C, Belleville-Nabet F, Bertrand F, Penin F, Cuny G, et al. Assessment of the clinical value of urinary trypsin inhibitory activity in elderly people. Age Aging 1992; 21: 456–62. 10.1093/ageing/21.6.456Search in Google Scholar

17 Piette M, Saba J, Bernard N, Pougheon M, Abat O, Fermanian J, et al. Urinary trypsin inhibitory activity for the diagnosis of bacterial infection: a prospective study in 690 patients. Eur J Med 1992; 1: 273–6. Search in Google Scholar

18 Pugia MJ, Takemura T, Kuwajima S, Suzuki M, Cast TK, Profitt JA, et al. Clinical utility of a rapid test for uristatin. Clin Biochem 2002; 35: 105–10. 10.1016/S0009-9120(02)00288-6Search in Google Scholar

19 Jortani SA, Pugia MJ, Elin RJ, Thomas M, Womack EP, Cast TK, et al. A sensitive non-invasive marker for diagnosis of probable bacterial or viral infection. J Clin Lab Anal 2004; 18: 289–95. 10.1002/jcla.20040Search in Google Scholar PubMed PubMed Central

20 Pugia MJ, Sommer R, Corey P, Lott JA, Anderson L, Gleason S, et al. The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections. Clin Chim Acta 2004; 341: 73–81. 10.1016/j.cccn.2003.10.019Search in Google Scholar PubMed

21 Takemura T, Nakano H, Kuwajma S. A clinical study of urinary trypsin inhibitor, an acute phase reactant in urine, in acute pediatric infectious diseases. Jpn J Inflamm 1994; 14: 53–7. Search in Google Scholar

22 Mizon C, Piva F, Queyrel V, Balduyck M, Hachulla E, Mizon J. Urinary bikunin determination provides insight into proteinase/proteinase inhibitor imbalance in patients with inflammatory diseases. Clin Chem Lab Med 2002; 40: 579–86. 10.1515/CCLM.2002.100Search in Google Scholar PubMed

23 Pratt CW, Swaim MW, Pizzo, SV. Inflammatory cells degrade inter-alpha-inhibitor to liberate urinary proteinase inhibitors. J Leuk Biol 1989; 45: 1–9. 10.1002/jlb.45.1.1Search in Google Scholar PubMed

24 Lindstroem KE, Blom A, Johnsson E, Haraldsson B, Fries E. High glomerular permeability of bikunin despite similarity in charge and hydrodynamic size to serum albumin. Kidney Int 1997; 51: 1053–8. 10.1038/ki.1997.147Search in Google Scholar PubMed

25 Ohlson M, Sorensson J, Lindstrom K, Blom AM, Fries E, Haraldsson B. Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol 2001; 281: F103–13. 10.1152/ajprenal.2001.281.1.F103Search in Google Scholar PubMed

26 Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Fujie M, et al. Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8. J Biol Chem 2001; 276: 13650–6. 10.1074/jbc.M009906200Search in Google Scholar PubMed

27 Kanayama N, Maehara K, Suzuki M, Fujise Y, Terao T. The role of chondroitin sulfate chains of urinary trypsin inhibitor in inhibition of LPS-induced increase of cytosolic free Ca 2+ in HL60 cells and HUVEC cells. Biochem Biophys Res Commun 1997; 238: 560–4. 10.1006/bbrc.1997.7344Search in Google Scholar PubMed

28 Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003; 116: 1863–73. 10.1242/jcs.00407Search in Google Scholar PubMed

29 Wakayama T, Mizushima S, Hirose J, Iseki S. Urinary trypsin inhibitor: production in the liver and reabsorption in the kidney of the rat. Acta Histochem Cytochem 1996; 29: 227–36. 10.1267/ahc.29.227Search in Google Scholar

30 Nakakuki M, Yamasaki F, Shinkawa T, Kudo M, Watanabe M, Mizota M. Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats. Can J Physiol Pharmacol 1996; 74: 104–11. 10.1139/y95-232Search in Google Scholar

31 Shikimi T, Suzuki S, Kaku K, Ishino H, Okunishi H, Takaori S. Sex- and age-related changes in urinary contents of alpha-1-microglobulin and ulinastatin in mice. Clin Exp Pharmacol Physiol 1999; 26: 614–7. 10.1046/j.1440-1681.1999.03093.xSearch in Google Scholar PubMed

32 Markiewicz A. Urinary antitrypsin activity in acute renal failure. Pol Arch Med Wewn 1970; 45: 661–7. Search in Google Scholar

33 Olear T, Nouza K. Thrombin and trypsin receptors: the same mechanism of signaling on cellular surfaces. Bratisl Lek Listy 1999; 100: 75–9. Search in Google Scholar

34 Brinkmann T, Schaefers J, Guertler L, Kido H, Niwa Y, Katunuma N, et al. Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologs. J Protein Chem 1997; 16: 651–60. 10.1023/A:1026379109403Search in Google Scholar

35 Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003; 384: 749–54. 10.1515/BC.2003.083Search in Google Scholar

36 Egeblad K, Astrup T. Fibrinolysis and the trypsin inhibitor in human urine. Scand J Clin Lab Invest 1966; 18: 181–90. 10.3109/00365516609051813Search in Google Scholar

37 Morishita H, Yamakawa T, Matsusue T, Kusuyama T, Sameshima-Aruga R, Hirose J, et al. Novel factor Xa and plasma kallikrein inhibitory activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor. Thromb Res 1994; 73: 193–204. 10.1016/0049-3848(94)90098-1Search in Google Scholar

38 Sumi H, Hamada H, Yoshida E, Tsushima H, Maruyama M, Mihara H. Chemical modification and anti-fibrinolysis of urinary trypsin inhibitor (UTI). Ketsueki Myakkan 1988; 19: 668–71. Search in Google Scholar

39 Mania-Pramanik J, Potdar SS, Vadigoppula A, Sawant S. Elastase: a predictive marker of inflammation and/or infection. J Clin Lab Anal 2004; 18: 153–8. 10.1002/jcla.20015Search in Google Scholar

40 Campbell DJ. Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides. Br J Med Biol Res 2000; 33: 665–77. 10.1590/S0100-879X2000000600008Search in Google Scholar

41 Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001; 28: 1060–5. 10.1046/j.1440-1681.2001.03564.xSearch in Google Scholar

42 Johnson R, Couser W, Alpers C, Vissers M, Schulze M. The human neutrophil serine proteinases, elastase and cathepsin G can mediate glomerular injury in vivo. J Exp Med 1988; 168: 1169–74. 10.1084/jem.168.3.1169Search in Google Scholar

43 Bromke BJ, Kueppers F. The major urinary protease inhibitor: simplified purification and characterization. Biochem Med 1982; 27: 56–67. 10.1016/0006-2944(82)90008-4Search in Google Scholar

44 Nakatani K, Takeshita S. Vascular endothelial cell injury by activated neutrophil and treatment for the injury. Surg Trauma Immunol Response 1999; 8: 112–4. Search in Google Scholar

45 Isogai R, Matsukura A, Aragane Y, Maeda A, Matsukura M, Yudate T, et al. Quantitative analysis of bikunin-laden mast cells in follicular eruptions and chronic skin lesions of atopic dermatitis. Arch Dermatol Res 2002; 294: 387–92. 10.1007/s00403-002-0336-9Search in Google Scholar PubMed

46 Cowan B, Baron O, Crack J, Coulber C, Wilson GJ, Rabinovitch ME. A serine elastase inhibitor attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J Clin Invest 1996; 97: 2452–68. 10.1172/JCI118692Search in Google Scholar

47 Fujita H, Morita I, Murota S. Cytoprotective effect of protease inhibitors on vascular endothelial cell injury induced by PMA-stimulated leukocytes. Ensho 1991; 11: 501–2. 10.2492/jsir1981.11.501Search in Google Scholar

48 Kato K, Nagao Y, Kurosawa M. Effect of human urinary trypsin inhibitor (ulinastatin) on inflammatory mediators from leukocytes: a possible role in the prevention of SIRS. Igaku Yakugaku 1995; 34: 499–506. Search in Google Scholar

49 Kanayama N, Maehara K, She L, Belayet H, Khatun S, Tokunaga N, et al. Urinary trypsin inhibitor suppresses vascular smooth muscle contraction by inhibition of Ca 2+ influx. Biochim Biophys Acta 1998; 1381: 139–46. 10.1016/S0304-4165(98)00022-1Search in Google Scholar

50 Imokawa H. Substances influencing the vascular permeability of an ear burn model in mice. The effectiveness of antihistamines. Sei Marianna Ika Daigaku Zasshi 1991;19:310–7. Search in Google Scholar

51 Imokawa H, Ando K, Kubota T, Isono E, Inoue H, Ishida H. Study on the kinetics of bradykinin level in the wound produced by thermal injury in the ear burn model in mice. Nippon Yakurigaku Zasshi 1992; 99: 445–50. 10.1254/fpj.99.445Search in Google Scholar

52 Takada K, Komori M, Notoya A, Tomizawa Y, Ozaki M. Effect of ulinastatin on microcirculation during excessive hemorrhage using fluid therapy. In Vivo 2003; 17: 129–36. Search in Google Scholar

53 Hirano T, Manabe T. Human urinary trypsin inhibitor, urinastatin, prevents pancreatic injuries induced by pancreaticobiliary duct obstruction with caerulein stimulation and systemic hypotension in the rat. Arch Surg 1993; 128: 1322–9. 10.1001/archsurg.1993.01420240030004Search in Google Scholar

54 Shinohara H, Kobayashi H, Hirashima Y, Ohi H, Terao T. Urinary trypsin inhibitor (UTI) efficiently inhibits tumor cell invasion and metastasis in the experimental and spontaneous model. J Jpn Soc Cancer Ther 1996; 3: 186–95. Search in Google Scholar

55 Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci 2004; 9: 1450–82. 10.2741/1347Search in Google Scholar

56 Takahashi M, Sawaguchi T, Sawaguchi A, Suzuki T. The cytoprotective effect of protease inhibitor on programmed cell death of endothelial cell. Tokyo Joshi Ika Daigaku Zasshi 2001;71:669–78. Search in Google Scholar

57 Onai H, Kudo S. Suppression of superantigen-induced lung injury and vasculitis by pre-administration of human urinary trypsin inhibitor. Eur J Clin Invest 2001; 31: 272–80. 10.1046/j.1365-2362.2001.00784.xSearch in Google Scholar

58 Wilharm E, Parry MAA, Friebel R, Tschesche H, Matschiner G, Sommerhoff CP, et al. Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. J Biol Chem 1999; 274: 27331–7. 10.1074/jbc.274.38.27331Search in Google Scholar

59 Hashimoto K, Nagao Y, Kato K, Mori Y, Ito A. Human urinary trypsin inhibitor inhibits the activation of pro-matrix metalloproteinases and proteoglycans release in rabbit articular cartilage. Life Sci 1998; 63: 205–13. 10.1016/S0024-3205(98)00261-6Search in Google Scholar

60 Delaria KA, Muller DK, Marlor CW, Brown JE, Das RC, Roczniak SO, et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12209–14. 10.1074/jbc.272.18.12209Search in Google Scholar PubMed

61 Potempa J, Kwon K, Chawla R, Travis J. Inter-alpha-trypsin inhibitor. Inhibition spectrum of native and derived forms. J Biol Chem 1989; 264: 15109–14. 10.1016/S0021-9258(18)63818-9Search in Google Scholar

62 Hirose J, Ozawa T, Miura T, Isaji M, Nagao Y, Yamashiro K, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor-related-proteins. Biol Pharm Bull 1998; 21: 651–6. 10.1248/bpb.21.651Search in Google Scholar

63 Nii A, Morishita H, Hirose J, Yamakawa T, Kanamori T. Novel blood coagulation factor inhibitory activities of the second domain of urinary trypsin inhibitor and its variants. Nippon Kessen Shiketsu Gakkaishi 1995; 6: 203–7. 10.2491/jjsth.6.203Search in Google Scholar

64 Nii A, Morishita H, Yamakawa T, Matsusue T, Hirose J, Miura T, et al. Design of variants of the second domain of urinary trypsin inhibitor (R-020) with increased factor Xa inhibitory activity. J Biochem 1994; 115: 1107–12. 10.1093/oxfordjournals.jbchem.a124465Search in Google Scholar

65 Brakman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase-induced fibrinolysis. Scand J Clin Lab Invest 1963; 15: 603–9. 10.3109/00365516309051342Search in Google Scholar

66 Egeblad K, Astrup T. Alpha-aminocaproic acid and urinary trypsin inhibitor: potentiated inhibition of urokinase-induced fibrinolysis. Proc Soc Exp Biol Med 1963; 112: 1022. 10.3181/00379727-112-28240Search in Google Scholar

67 Lorand L, Condit EV. Ester hydrolysis by urokinase. Biochemistry 1965; 4: 265–70. 10.1021/bi00878a014Search in Google Scholar

68 Speer C, Rechwilm M, Tegtmeyer F, Gahr M. Elastase-alpha-PI: early indicator of infections in pediatric patients. Second Vienna Shock Forum, 1989:689–93. Search in Google Scholar

69 Creighton TE. Protein structure and molecular properties. New York: WH Freeman & Co, 1984:253–5. Search in Google Scholar

70 Cocks T, Moffatt J. Protease-activated receptors: sentries for inflammation. Trends Pharmacol Sci 2000; 21: 103–8. 10.1016/S0165-6147(99)01440-6Search in Google Scholar

71 Cottrell G. Protease activated receptors: the role of cell surface proteolysis in signaling. Essays Biochem 2002; 38: 169–83. 10.1042/bse0380169Search in Google Scholar PubMed

72 Miike S, McWilliam A, Kita H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J Immunol 2001; 167: 6615–22. 10.4049/jimmunol.167.11.6615Search in Google Scholar PubMed

73 Shibutani Y, Kunihiro Y. Preventive effects of urinastatin on tissue degradation. Yakuri Chiryo 1986; 14: 6057–72. Search in Google Scholar

74 Lott JA. Transplantation of the pancreas or pancreatic islet cells: a clinical perspective. In: Lott JA, editor. Clinical pathology of pancreatic disorders. Totowa, NJ: Humana Press 1997:1–26. 10.1007/978-1-4612-3964-2_1Search in Google Scholar

75 Ogawa K, Hasegawa Y, Nikai T, Sugihara H, Takagi K. Elastase from Aspergillus fumigatus, its pathogenetic role and inhibitor. Nippon Ishinkin Gakkai Zasshi 1997; 38: 149–53. 10.3314/jjmm.38.149Search in Google Scholar

76 Kadowaki T, Takii R, Baba A, Yamamoto K. Gingipains as the determinants of periodontopathogenicity. Nippon Yakurigaku Zasshi 2003; 122: 37–44. 10.1254/fpj.122.37Search in Google Scholar

77 Sidhu SS, Kalmar GB, Willis LG, Borgford TJ. Protease evolution in Streptomyces griseus. Discovery of a novel dimeric enzyme. J Biol Chem 1995; 270: 7594–600. 10.1074/jbc.270.13.7594Search in Google Scholar

78 Brain SD. New feelings about the role of sensory nerves in inflammation. Nat Med 2000; 6: 134–5. 10.1038/72218Search in Google Scholar

79 Kuwajima S, Izumi Y, Noda T, Kitao H, Kishida T, Naka K, et al. Automated measurement of urinary trypsin inhibitor, an acute phase reactant in urine. Int Cong Ser Prog Clin Biochem 1992; 991: 317–20. Search in Google Scholar

80 Fink E, Godec G, Arnhold M, Nawratil P. Utilization of polyspecific antiserum for specific radioimmunoassays: radioimmunoassays for rat fetuin and bikunin were developed by using antiserum against total rat serum proteins. Anal Lett 1993; 26: 2587–94. 10.1080/00032719308017976Search in Google Scholar

81 Noda T. The immunoassay of human urinary trypsin indicator and its clinical significance as an acute-phase reactant. J Osaka City Med Cent 1992; 41: 489–500. Search in Google Scholar

82 Ogloblina O, Beckert R, Belova L, Bauer M, Smirnov M. Monoclonal antibodies that recognize trypsin binding domain of human urinary trypsin inhibitor. Hybridoma 1993; 12: 745–54. 10.1089/hyb.1993.12.745Search in Google Scholar

83 Shikimi T, Suzuki S, Takahashi M, Kaneto H. Sandwich enzyme-immunoassay of human urinary trypsin inhibitor (urinastatin) and urinastatin-like immunoreactive substance in mouse urine. Scand J Clin Lab Invest 1990; 50: 1–8. 10.3109/00365519009091558Search in Google Scholar

84 Ukai R. Immunohistochemical localization of human urinary trypsin inhibitor (UTI) in normal and fetal kidney and renal cancer tissue. Hiroshima Daigaku Igaku Zasshi 1986; 34: 837–47. Search in Google Scholar

85 Nishino N, Aoki K, Tokura Y, Sakaguchi S, Fujie M, Sugawara Y, et al. Measurement of urinary trypsin inhibitor in urine, plasma, and cancer tissues of patients with stomach cancer. Haemostasis 1989; 19: 112–9. Search in Google Scholar

86 Faarvang HJ. Spontaneous individual variations of the normal 24-hour excretion of trypsin inhibitor in urine. Scand J Clin Lab Invest 1962; 14: 132–7. 10.3109/00365516209079684Search in Google Scholar

87 Kuwajima S, Noda T, Izumi Y, Kitao H, Naka K, Okuda K. Urinary trypsin inhibitor as an acute phase reactant. Rinsho Byori 1992; 40: 751–5. Search in Google Scholar

88 Mayehiro A. Trypsin inhibitor in urine. I. The trypsin inhibitor of the urine of normal persons. Yokohama Med Bull 1959; 10: 329–36. Search in Google Scholar

89 Newman D, Pugia M, Lott JA, Wallace J, Hiar J. Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta 2000; 294: 139–55. 10.1016/S0009-8981(00)00181-9Search in Google Scholar

90 Gosset D, Mizon C, Savinel P, Balduyck M, Boniface B, Hatron PY, et al. Value of urinary trypsin inhibitory capacity determination. Presse Med 1988; 17: 329–32. Search in Google Scholar

91 Ueki M, Yokano S, Taya S, Nosuga J, Komatsu H, Oguri K. Changes in urine urinastatin discharge amount and C reactive protein after gastrectomy. Anesthesia 1996; 45: 933–6. Search in Google Scholar

92 Du Clos T. Function of C-reactive protein. Am Med 2000; 32: 274–8. 10.3109/07853890009011772Search in Google Scholar PubMed

93 Gershov D, Kim S, Brot N, Elkon K. C-Reactive protein binds to apoptotic cells. J Exp Med 2000; 192: 1353–63. 10.1084/jem.192.9.1353Search in Google Scholar PubMed PubMed Central

94 Deodhar S. C-Reactive protein: the best laboratory indictor available for monitoring disease activity. Cleve Clin J Med 1989; 56: 126–30. 10.3949/ccjm.56.2.126Search in Google Scholar PubMed

95 Jaye DL, Waits KB. Clinical applications of C-reactive protein in paediatrics. Pediatr Infect Dis J 1997; 16: 735–47. 10.1097/00006454-199708000-00003Search in Google Scholar PubMed

96 Da Silva O, Ohlsson A, Kenyon C. Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review. Pediatr Infect Dis J 1995; 14: 362–6. 10.1097/00006454-199505000-00005Search in Google Scholar PubMed

97 Yentis SM, Soni N, Sheldon J. C-Reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med 1995; 21: 602–5. 10.1007/BF01700168Search in Google Scholar PubMed

98 Abramson JS, Hampton KD, Babu S. The use of C-reactive protein from cerebrospinal fluid for differentiating meningitis from other central nervous system diseases. J Infect Dis 1985; 151: 854–8. 10.1093/infdis/151.5.854Search in Google Scholar PubMed

99 Benjamin DR, Opheim KE, Brewer L. Is C-reactive protein useful in the management of children with suspected bacterial meningitis? Am J Clin Pathol 1984; 81: 779–82. 10.1093/ajcp/81.6.779Search in Google Scholar PubMed

100 Dias LR, Alves Ribeiro M, Farhat CK. CRP follow-up of children with acute bacterial meningitis. Braz J Infect Dis 1999; 3: 15–22. Search in Google Scholar

101 Tatara R, Imai H. Serum CRP in differential diagnosis of childhood meningitis. Pediatr Int 2000; 42: 541–6. 10.1046/j.1442-200x.2000.01285.xSearch in Google Scholar PubMed

102 Erkasap S, Ates E, Ustuner Z. Diagnostic value of IL-6 and C-reactive protein in acute appendicitis. Swiss Surg 2000; 6: 169–72. 10.1024/1023-9332.6.4.169Search in Google Scholar PubMed

103 Heishanen-Kosma T, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral etiology of community acquired pneumonia. Scand J Infect Dis 2000; 32: 399–402. 10.1080/003655400750044971Search in Google Scholar

104 Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206–17. 10.1086/421997Search in Google Scholar

105 Franz AR, Steinbach G, Kron M, Pohlandt F. Reduction of unnecessary antibiotic therapy in newborn infants using IL-8 and C-reactive protein as markers of bacterial infections. Pediatrics 1999; 447–53. 10.1542/peds.104.3.447Search in Google Scholar

106 Isaacman DJ, Burke BL. Utility of the serum C-reactive protein in detection of occult bacterial infections in children. Arch Pediatr Adolesc Med 2002; 156: 905–9. 10.1001/archpedi.156.9.905Search in Google Scholar

107 Roine I, Faingezicht I, Arguedas A, Herrera JF, Rodriguez F. Serial serum C-reactive protein to monitor recovery from acute haematogenous osteomyelytis in children. Pediatr Infect Dis J 1995; 14: 56–9. 10.1097/00006454-199501000-00008Search in Google Scholar

108 Barland P, Lipstein E. Selection and uses of laboratory tests in rheumatic diseases. Am J Med 1996; 100: 16s–20s. 10.1016/S0002-9343(97)89542-3Search in Google Scholar

109 Thompson D, Milford-Ward A, Whicher JT. The value of acute phase protein measurements in clinical practice. Ann Clin Biochem 1992; 29: 123–31. 10.1177/000456329202900201Search in Google Scholar PubMed

110 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leucocyte count with coronary heart disease: meta-analysis of perspective studies. J Am Med Assoc 1998; 279: 1477–82. 10.1001/jama.279.18.1477Search in Google Scholar PubMed

111 Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–8. 10.1161/01.CIR.102.18.2165Search in Google Scholar PubMed

112 Ridker P, Rifai N, Rose L, Buring J, Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65. 10.1056/NEJMoa021993Search in Google Scholar PubMed

113 Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M. Determination of raised CRP concentration in type 1 diabetes. Q J Med 2000; 93: 231–6. 10.1093/qjmed/93.4.231Search in Google Scholar

114 Santolaya ME, Cofre J, Beresi V. C-Reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994; 18: 589–95. 10.1093/clinids/18.4.589Search in Google Scholar

115 Eisenberg MS, Chek HJ, Washofsky MK, Sciacca RR, Wasserman HS, Schwartz A, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant patients. Circulation 2000; 102: 2100–4. 10.1161/01.CIR.102.17.2100Search in Google Scholar

116 Escobar GJ. Effect of the systemic inflammatory response on biochemical markers of neonatal bacterial infection: a fresh look at old confounders. Clin Chem 2003; 49: 21–2. 10.1373/49.1.21Search in Google Scholar

117 Chiesa C, Pellegrini G, Panero A, Osborn J, Signore F, Assumma M, et al. C-Reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49: 60–8. 10.1373/49.1.60Search in Google Scholar

118 Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen M, et al. Serum procalcitonin, C-reactive protein, IL-6 in distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000;vol: 598–602. 10.1097/00006454-200007000-00003Search in Google Scholar

119 Hotta O, Yusa N, Ooyama M, Unno K, Furuta T, Taguma Y. Detection of urinary macrophages expressing the CD16 molecule: a novel marker of acute inflammatory glomerular injury. Kidney Int 1999; 55: 1927–34. 10.1046/j.1523-1755.1999.00431.xSearch in Google Scholar

120 Huang F, Horikoshi S, Kurusu A, Shibata T, Suzuki S, Funabiki K, et al. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy. J Clin Lab Anal 2001; 15: 30–4. 10.1002/1098-2825(2001)15:1<30::AID-JCLA6>3.0.CO;2-XSearch in Google Scholar

121 Koizumi R, Kanai H, Maezawa A, Kanda T, Nojima Y, Naruse T. Therapeutic effects of ulinastatin on experimental crescentic glomerulonephritis in rats. Nephron 2000; 84: 347–53. 10.1159/000045610Search in Google Scholar

122 Onbe T, Makino H, Haramoto T, Wada J, Ogura T, Kumagai I, et al. Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect. Jpn J Nephrol 1991; 33: 753–9. Search in Google Scholar

123 Mayehiro A. Studies of trypsin inhibitor in urine. II. Trypsin inhibitor of the urine in various pediatric patients. Yokohama Med Bull 1960; 11: 111–24. Search in Google Scholar

124 Cochrane CG, Unanue ER, Dixon FJ. A role of polymorphonuclear leukocyte and complement in nephrotoxic nephritis. J Exp Med 1965; 122: 99–116. 10.1084/jem.122.1.99Search in Google Scholar

125 Itabashi K, Takahashi T, Ito Y, Ishii K, Sato K, Kakita A. Protective effects of urinary trypsin inhibitor on hepatic microvascular injury in hypotensive brain-dead rats. Transplant Proc 2003; 35: 114–6. 10.1016/S0041-1345(02)03970-2Search in Google Scholar

126 Nakatani K, Takeshita S. Vascular endothelial cell injury by activated neutrophils and treatment for the injury. Surg Trauma Immunol Response 1999; 8: 112–4. Search in Google Scholar

127 Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leuk Biol 2001; 69: 241–7. 10.1189/jlb.69.2.241Search in Google Scholar

128 Tomino Y. IgA nephropathy: from molecules to men. contributions to nephrology, vol. 126. Basel, Switzerland: Karger, 1999:1–115. 10.1159/isbn.978-3-318-00402-1Search in Google Scholar

129 Taha AS, Grant V, Kelly RW. Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J 2003; 79: 159–63. 10.1136/pmj.79.929.159Search in Google Scholar

130 Nagai T. The effect of pancreatic elastase on diabetic nephropathy. Diabetes Res Clin Pract 1994; 24: 164–5. 10.1016/0168-8227(94)90111-2Search in Google Scholar

131 Taubes G. Does inflammation cut to the heart of the matter. Science 2002; 296: 242–5. 10.1126/science.296.5566.242Search in Google Scholar PubMed

132 Aihara T, Shiraishi M, Hiroyasu S, Hatsuse K, Mochizuki H, Seki S, et al. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by down-regulating TNF-alpha in the liver. Transplant 1998; 30: 3732–4. Search in Google Scholar

133 Kaneko H. Injury mechanisms by neutrophil elastase and cytokines in a liver ischemia model and the countermeasures. Surg Trauma Immunol Response 2002; 11: 91–3. Search in Google Scholar

134 Okajima K. Therapy of shock-induced renal injury by UTI. Surg Trauma Immunol Response 2002; 11: 114–7. Search in Google Scholar

135 Okuhama Y, Shiraishi M, Higa T, Tomori H, Taira K, Mamadi T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999; 82: 34–42. 10.1006/jsre.1998.5496Search in Google Scholar PubMed

136 Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, et al. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 2000; 94: 107–15. 10.1006/jsre.2000.5999Search in Google Scholar PubMed

137 Takada K, Komori M, Notoya A, Tomizawa Y, Ozaki M. Effect of ulinastatin on microcirculation during excessive hemorrhage using fluid therapy. In Vivo 2003; 17: 129–36. Search in Google Scholar

138 Chao J, Stallone J, Liang Y, Chen L, Wang D, Chao L. Kallistatin is a potent new vasodilator. J Clin Invest 1997; 100: 11–7. 10.1172/JCI119502Search in Google Scholar PubMed PubMed Central

139 Takahashi M, Sawaguchi T, Sawaguchi A, Suzuki T. The cytoprotective effect of protease inhibitor on programmed cell death of endothelial cell. Tokyo Joshi Ika Daigaku Zasshi 2001; 71: 669–78. Search in Google Scholar

140 Kaplan A, Silverberg M, Dunn J, Ghebrehiwet B. Interaction of the clotting, kinin forming, complement, and fibrinolytic pathways in inflammation. Ann NY Acad Sci 1982; 389: 25–38. 10.1111/j.1749-6632.1982.tb22123.xSearch in Google Scholar PubMed

141 Murakami M. Effect of protease inhibitors on endotoxin-induced disseminated intravascular coagulation in rats. Kyoto Ika Daigaku Zasshi 1988; 97: 1155–65. Search in Google Scholar

142 Eguchi Y. DIC-induced organ failure. Igaku Ayumi 2003; 206: 19–22. Search in Google Scholar

143 Nii A, Morishita H, Yamakawa T, Matsusue T, Hirose J, Miura T, et al. Design of variants of the second domain of urinary trypsin inhibitor (R-020) with increased factor Xa inhibitory activity. J Biochem 1994; 115: 1107–12. 10.1093/oxfordjournals.jbchem.a124465Search in Google Scholar PubMed

144 Sakuragawa N, Shimotori T, Takahashi K, Niwa M. Effect of urinastatin on coagulation, fibrinolysis, and platelet aggregation in vitro and in vivo. Saishin Igaku 1987; 42: 820–30. Search in Google Scholar

145 Fabris C, Basso D, Naccarato R. Urinary enzymes excretion in pancreatic disease. J Clin Gastroenterol 1992; 14: 281–4. 10.1097/00004836-199206000-00003Search in Google Scholar

146 Fabris C, Basso D, Benini L, Meggiato T, Del Favero G, Cavallini G, et al. Urinary elastate 1 in chronic pancreatic disease. Enzyme 1989; 42: 80–6. 10.1159/000469013Search in Google Scholar

147 Weber C, Adler G. From acinar cell damage to systemic inflammatory response. Curr Concepts Pancreatitis Pancreatol 2001; 1: 356–62. Search in Google Scholar

148 Kazmierczak SC. Biochemical indicators of acute pancreatitis. In: Lott JA, editor. Clinical pathology of pancreatic disorders. Totowa, NJ: Humana Press, 1997:75–124. Search in Google Scholar

149 Gwozdz G, Steinberg W, Werner M, Henry J, Pauley C. Comparative evaluation of the diagnosis of acute pancreatitis based on serum and urine enzyme assays. Clin Chim Acta 1990; 187: 243–54. 10.1016/0009-8981(90)90109-6Search in Google Scholar

150 Sugita T, Wartarida S, Katsuyama K, Nakajima Y, Yamamoto R, Mori A. Effect of a human urinary protease inhibitor (ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg 2002; 43: 437–40. Search in Google Scholar

151 Matsumi M, Takashima T. Endogenous UTI and prognosis in sepsis. Surg Trauma Immunol Response 2001; 10: 20–4. Search in Google Scholar

152 Hamazaki K, Matsubara N, Edahiro T, Sodeki Y, Mimura T, Mori M. Granulocytic elastase after hepatic resection, effect of urinastatin on change in IL-6. Clin Res 1994; 71: 213–6. Search in Google Scholar

153 Nishiyama T, Hanaoka K. Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6? Crit Care Med 2001; 29: 2106–10. 10.1097/00003246-200111000-00010Search in Google Scholar PubMed

154 Ambiru S, Miyazaki M, Sasada K, Ito H, Kimura F, Nakagawa K, et al. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Digest Surg 2000; 17: 337–43. 10.1159/000018875Search in Google Scholar PubMed

155 Okumura Y, Inoue H, Fujiyama Y, Bamba T. Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats. J Gastroenterol 30 1995; 379–86. 10.1007/BF02347515Search in Google Scholar PubMed

156 Kaneko H. Injury mechanisms by neutrophil elastase and cytokines in a liver ischemia model and the countermeasures. Surg Trauma Immunol Response 2002; 11: 91–3. Search in Google Scholar

157 Yoshino M. Contribution of TNF-alpha and IL-6 in hepatic ischemia reperfusion injury. Toho Igakkai Zasshi 1996; 42: 530–43. Search in Google Scholar

158 Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y, et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by over-expression of bikunin. Int J Cancer 2003; 104: 289–302. 10.1002/ijc.10950Search in Google Scholar PubMed

159 Kobayashi H, Sugino D, Terao T. Urinary trypsin inhibitor, a Kunitz-type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells. Int J Oncol 1998; 12: 95–105. 10.3892/ijo.12.1.95Search in Google Scholar

160 Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003; 384: 749–54. 10.1515/BC.2003.083Search in Google Scholar PubMed

161 Hirashima Y, Suzuki M, Kobayashi H. Suppression of cancer invasion and metastasis in human ovarian cancer cells transfected with UTI gene. Surg Trauma Immunol Response 2001; 10: 30–6. Search in Google Scholar

162 Kobayashi H, Gotoh J, Hirashima Y, Terao T. Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface. J Biol Chem 1996; 271: 11362–7. 10.1074/jbc.271.19.11362Search in Google Scholar PubMed

163 Kobayashi H, Hirashima Y, Sun Guang W, Fujie M, Nishida T, Takigawa M, et al. Identity of urinary trypsin inhibitor-binding protein to link protein. J Biol Chem 2000; 275: 21185–91. 10.1074/jbc.M907862199Search in Google Scholar

164 Kobayashi H, Sugino D, She MY, Ohi H, Hirashima Y, Shinohara H, et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998; 253: 817–26. 10.1046/j.1432-1327.1998.2530817.xSearch in Google Scholar

165 Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Terao T. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta 2001; 1547: 26–36. 10.1016/S0167-4838(01)00167-4Search in Google Scholar

166 Takubo T, Kumura T, Nakamae H, Aoyama Y, Koh KR, Ohta K, et al. Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies. Haematology 2001; 31: 267–72. 10.1163/15685590152763836Search in Google Scholar PubMed

167 Takubo T, Kuwajima S, Tatsumi N. Clinical usefulness of urinary trypsin inhibitor in hematological disorders. Igaku Seibutsugaku 1997; 134: 25–8. Search in Google Scholar

168 Brinkmann T, Weilke C, Kleesiek K. Recognition of acceptor proteins by UDP-D-xylose proteoglycan core protein β-D-xylosyltransferase. J Biol Chem 1997; 272: 11171–5. 10.1074/jbc.272.17.11171Search in Google Scholar PubMed

169 Yoneda M, Kimata K. Hyaluronan-rich extracellular matrix. A role of inter-alpha-trypsin inhibitor, serum derived proteoglycan. Seikagaku 1995; 67: 458–65. Search in Google Scholar

170 Zhuo L, Salustri A, Kimata K. A physiological function of serum proteoglycan bikunin: the chondroitin sulfate moiety plays a central role. Glycoconj J 2002; 19: 241–7. 10.1023/A:1025331929373Search in Google Scholar

171 Zhuo L, Yoneda M, Zhao M, Yingsung W, Yoshida N, Kitagawa Y, et al. Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. J Biol Chem 2001; 276: 7693–6. 10.1074/jbc.C000899200Search in Google Scholar PubMed

172 Hochstrasser K, Schoenberger OL, Rossmanith I, Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor. V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe-Seyler Z Physiol Chem 1981; 362: 1357–62. 10.1515/bchm2.1981.362.2.1357Search in Google Scholar PubMed

173 Kato Y, Kudo M, Shinkawa T, Mochizuki H, Isaji M, Shiromizu I, et al. Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Biochem Biophys Res Commun 1998; 243: 377–83. 10.1006/bbrc.1998.8100Search in Google Scholar PubMed

174 Mizon C, Mairie C, Balduyck M, Hachulla E, Mizon J. The chondroitin sulfate chain of bikunin-containing proteins in the inter-alpha-inhibitor family increases in size in inflammatory diseases. Eur J Biochem 2001; 268: 2717–24. 10.1046/j.1432-1327.2001.02168.xSearch in Google Scholar PubMed

175 Capon C, Mizon C, Lemoine J, Rodié-Talbère P, Mizon J. In acute inflammation, the chondroitin-4 sulphate carried by bikunin is not only longer; it is also undersulphated. Biochimie 2003; 85: 101–7. 10.1016/S0300-9084(03)00066-XSearch in Google Scholar

176 Yamada S, Oyama M, Yuki Y, Kato K, Sugahara K. The uniform galactose 4-sulfate structure in the carbohydrate-protein linkage region of human urinary trypsin inhibitor. Eur J Biochem 1995; 233: 687–93. 10.1111/j.1432-1033.1995.687_2.xSearch in Google Scholar

177 Worcester , EM. Inhibitors of stone formation. Semin Nephrol 1996; 16: 474–86. Search in Google Scholar

178 Aoyama N, Minamiide J, Yoneyama K, Doi N, Kamiya J, Hoshino S, et al. Role of urinastatin administration in surgery for esophageal cancer – changes in cytokines and neutrophil elastase, and critical percentage of SIRS. Prog Med 1998; 18: 1724–7. Search in Google Scholar

179 Karasawa T, Uehara K, Yokota T, Nomoto S. Changes in blood cytokines in abdominal resection, and effect of urinastatin and blood transfusion. Rinsho Masui [Clin Anesth] 1996; 20: 1169–75. Search in Google Scholar

180 Matsumi M, Mizobuchi S, Kaku R, Ohashi I, Nakatsuka H, Katayama H. Changes in urinary trypsin inhibitor in blood and urine, as well as serum cytokines in living related liver transplantation. Anesthesia 2003; 52: 251–6. Search in Google Scholar

181 Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002; 48: 1681–8. Search in Google Scholar

182 Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 48: 17–29. 10.1016/S0009-8981(02)00101-8Search in Google Scholar

183 Song J, Yoon Y, Park K, Park J, Hong Y, Hong S, et al. Genotype-specific influence on nitric oxide synthase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells. Clin Chem 2003; 49: 847–52. 10.1373/49.6.847Search in Google Scholar PubMed